AC-RIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNS-NH2

AC-RIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNS-NH2 Chemische Eigenschaften,Einsatz,Produktion Methoden

• S-Sätze Betriebsanweisung:

  S22:Staub nicht einatmen.
  S24/25:Berührung mit den Augen und der Haut vermeiden.

• Verwenden

  Nogo-66(1-40) antagonist peptide has been used as a Nogo-66 receptor antagonist peptide:
  
  • to study the preliminary therapeutic effect after inhibition of Nogo-A in the cauda equina compression (CEC) model
  • to determine the effects of Nogo-A/NgR1 on autophagic activation
  • to study its role in Nogo-B mediated axonal branching using Schwann cells and sensory neurons of mice
  
  

• Biochem/physiol Actions

  Myelin-derived axon outgrowth inhibitors, such as Nogo, may account for the lack of axonal regeneration in the central nervous system (CNS) after trauma in adult mammals. Nogo-66 can inhibit axonal outgrowth through an axonal Nogo-66 receptor (NgR). Competitive antagonists of NgR derived from amino-terminal peptide fragments of Nogo-66. The Nogo-66(1 40) antagonist peptide (NEP1 40) blocks Nogo-66 or CNS myelin inhibition of axonal outgrowth in vitro, demonstrating that NgR mediates a significant portion of axonal outgrowth inhibition by myelin. Intrathecal administration of NEP1 40 to rats with mid-thoracic spinal cord hemisection results in significant axon growth of the corticospinal tract, and improves functional recovery. Thus, Nogo-66 and NgR have central roles in limiting axonal regeneration after CNS injury, and NEP1-40 provides a potential therapeutic agent.

• Lager

  Store at -20°C

AC-RIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNS-NH2 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(62)Suppliers